Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
J Clin Lipidol. 2021 Jan-Feb;15(1):192-201. doi: 10.1016/j.jacl.2020.11.008. Epub 2020 Nov 23.
After a dementia diagnosis, goals of care are often reassessed, including the use of preventive medications like statins.
To examine changes in statin use after initiating medication for managing dementia.
A case-crossover study utilizing medication dispensing data from the Australian Pharmaceutical Benefits Scheme (PBS) 10% random sample was conducted. Use of statins was compared in the 12 months pre- and post-initiation (pre-period and post-period) of anti-dementia medications or risperidone for behavioural symptoms of dementia. Individuals aged ≥65 years who had their first dispensing of anti-dementia medication or risperidone between July 2006 and June 2017 and survived ≥12 months after their first supply were included. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for change in statin use in the discordant pairs.
The cohort (n = 19,809) had a median age of 81 years and 61% were female. Statins were less likely to be used after initiating anti-dementia medication or risperidone (OR 0.50; 95%CI 0.45-0.55). The OR for statin use in the post-period versus the pre-period decreased annually over the 11 years from 1.21; 95%CI 0.84-1.75 in 2006-7 to 0.31; 95%CI 0.24-0.41 in 2016-17 (p for interaction <0.05).
Statins are more likely to be ceased than started after initiating medication for dementia. This may reflect changes in goals of care, or changes in the interpretation of the available evidence for the safety and efficacy of statins in older people living with dementia.
在诊断出痴呆症后,通常会重新评估治疗目标,包括使用预防药物,如他汀类药物。
研究在开始治疗痴呆症的药物后,他汀类药物的使用是否发生变化。
本研究采用病例交叉研究设计,利用澳大利亚药品福利计划(PBS)10%随机样本的药物配给数据。在开始使用抗痴呆药物或利培酮治疗痴呆行为症状的 12 个月内,比较他汀类药物在起始前(起始前和起始后)的使用情况。纳入标准为 2006 年 7 月至 2017 年 6 月期间首次配药抗痴呆药物或利培酮且首次供应后存活至少 12 个月的年龄≥65 岁的个体。采用条件逻辑回归估计在不一致对中他汀类药物使用变化的比值比(OR)和 95%置信区间(CI)。
队列(n=19809)的中位年龄为 81 岁,61%为女性。与起始抗痴呆药物或利培酮后相比,他汀类药物的使用可能性较低(OR 0.50;95%CI 0.45-0.55)。在起始后 11 年中,每年他汀类药物使用的 OR 从 2006-7 年的 1.21(95%CI 0.84-1.75)降至 2016-17 年的 0.31(95%CI 0.24-0.41)(p 值<0.05,交互作用检验)。
与起始治疗痴呆症的药物相比,开始治疗后更有可能停止使用他汀类药物。这可能反映了治疗目标的变化,或者反映了对他汀类药物在老年痴呆症患者中的安全性和疗效的现有证据的解释发生了变化。